Aquestive Therapeutics reported second quarter 2026 financial results, posting total revenues of $13.8 million compared to $10.0 million in the prior year period. The company recorded a net loss of $22.9 million, or $0.18 per share, driven largely by an $11.7 million one-time loss on the extinguishment of its 13.5% Notes. Excluding this non-cash charge, the adjusted net loss was $11.2 million. The firm completed required human factors and pharmacokinetic studies for Anaphylm, reaffirming plans to resubmit the New Drug Application to the FDA in Q3 2026. Cash and cash equivalents stood at $98.5 million as of June 30, 2026. Aquestive Therapeutics operates in the pharmaceutical industry, developing proprietary drug delivery technologies and manufacturing products for licensees.

Aquestive Therapeutics announced positive topline results from human factors and pharmacokinetic studies for Anaphylm™ (dibutepinephrine) sublingual film, supporting its planned resubmission of a New Drug Application to the FDA in the third quarter of 2026. The revised packaging reduced median time to open the pouch from 17 seconds to 3 seconds and decreased incorrect film placement by over 80% compared to previous studies. Pharmacokinetic data showed self-administration results comparable to clinician-administered doses, with a geometric mean Cmax of 391.7 pg/mL versus 357.6 pg/mL. The company plans to address deficiencies identified in a January 2026 Complete Response Letter regarding user interface and administration errors. Aquestive Therapeutics is a pharmaceutical company specializing in oral film delivery technologies for prescription drugs.